XML 39 R28.htm IDEA: XBRL DOCUMENT
v3.25.2

Summary of Significant Accounting Policies (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Summary Of Significant Accounting Policies [Line Items] |
Summary of Cash, Cash Equivalents and Restricted Cash | Cash as reported in the accompanying condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents and restricted cash as presented on the accompanying condensed consolidated balance sheets as follows:
|  | June 30, 2025 |  |  | December 31, 2024 |
|  | (in thousands) |
Cash and cash equivalents |  | $ | 748,953 |  |  | $ | 681,101 |
Restricted cash — included in “Prepaid expenses and other current assets” |  |  | 449 |  |  |  | 126 |
Restricted cash, non-current — included in “Other assets” |  |  | 1,698 |  |  |  | 2,017 |
Total cash, cash equivalents and restricted cash |  | $ | 751,100 |  |  | $ | 683,244 |
Summary of Other Current Liabilities | Other current liabilities presented on the condensed consolidated balance sheets consisted of the following balances:
|  | June 30, 2025 |  |  | December 31, 2024 |
|  | (in thousands) |
Accrued rebates and other related costs |  | $ | 19,065 |  |  | $ | 210 |
Accrued interest |  |  | 14,411 |  |  |  | 11,056 |
Accrued commercial liabilities |  |  | 11,326 |  |  |  | 11,267 |
Accrued professional services |  |  | 7,135 |  |  |  | 3,673 |
Deferred royalty obligations, current portion |  |  | 4,812 |  |  |  | 144 |
Milestone liabilities |  |  | 2,400 |  |  |  | 1,595 |
Income taxes payable |  |  | 2,100 |  |  |  | 1,153 |
Other accrued liabilities |  |  | 4,667 |  |  |  | 3,973 |
Total other current liabilities |  | $ | 65,916 |  |  | $ | 33,071 |
Summary of Segment Information for Revenue, Significant Operating Expenses and Other Income (Expense), and Net Loss | The following table summarizes our segment information for significant operating expenses and includes a reconciliation to net loss:
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | (in thousands) |  |  | (in thousands) |
Revenues: |  |  |  |  |  |  |  |  |  |  |  |
License and services revenue |  | $ | 37,440 |  |  | $ | 2,168 |  |  | $ | 117,130 |  |  | $ | 213,288 |
Net product revenue |  |  | 71,501 |  |  |  | — |  |  |  | 108,240 |  |  |  | — |
Royalty revenue |  |  | 1,624 |  |  |  | — |  |  |  | 1,828 |  |  |  | — |
Total revenues, net |  |  | 110,565 |  |  |  | 2,168 |  |  |  | 227,198 |  |  |  | 213,288 |
Operating costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenues: |  |  |  |  |  |  |  |  |  |  |  |
Cost of license, services and royalty revenue |  |  | 805 |  |  |  | 598 |  |  |  | 1,410 |  |  |  | 1,196 |
Cost of goods sold |  |  | 2,848 |  |  |  | — |  |  |  | 4,882 |  |  |  | — |
Total cost of revenues |  |  | 3,653 |  |  |  | 598 |  |  |  | 6,292 |  |  |  | 1,196 |
Research and development by significant program: |  |  |  |  |  |  |  |  |  |  |  |
Acoramidis for the treatment and primary prevention of ATTR-CM |  |  | 28,269 |  |  |  | 36,798 |  |  |  | 52,661 |  |  |  | 76,540 |
Infigratinib for achondroplasia and hypochondroplasia |  |  | 30,191 |  |  |  | 22,098 |  |  |  | 58,125 |  |  |  | 43,283 |
BBP-418 for LGMD2I/R9 |  |  | 11,243 |  |  |  | 10,773 |  |  |  | 25,452 |  |  |  | 20,791 |
Encaleret for ADH1 |  |  | 13,128 |  |  |  | 10,608 |  |  |  | 28,587 |  |  |  | 23,152 |
Other development programs |  |  | 10,536 |  |  |  | 9,693 |  |  |  | 21,966 |  |  |  | 41,977 |
Other research programs |  |  | 17,864 |  |  |  | 24,725 |  |  |  | 35,871 |  |  |  | 49,924 |
Total segment research and development |  |  | 111,231 |  |  |  | 114,695 |  |  |  | 222,662 |  |  |  | 255,667 |
Selling, general and administrative |  |  | 129,154 |  |  |  | 59,523 |  |  |  | 235,519 |  |  |  | 125,330 |
Restructuring, impairment and related charges |  |  | 805 |  |  |  | 2,891 |  |  |  | 1,375 |  |  |  | 6,291 |
Total operating costs and expenses |  |  | 244,843 |  |  |  | 177,707 |  |  |  | 465,848 |  |  |  | 388,484 |
Loss from operations |  |  | (134,278 | ) |  |  | (175,539 | ) |  |  | (238,650 | ) |  |  | (175,196 | )
Other income (expense), net: |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 3,898 |  |  |  | 5,195 |  |  |  | 9,283 |  |  |  | 9,270 |
Interest expense |  |  | (37,637 | ) |  |  | (22,937 | ) |  |  | (79,778 | ) |  |  | (46,408 | )
Gain on deconsolidation of a subsidiary |  |  | — |  |  |  | 126,294 |  |  |  | — |  |  |  | 126,294 |
Losses on extinguishments of debt |  |  | — |  |  |  | — |  |  |  | (21,155 | ) |  |  | (26,590 | )
Net loss from equity method investments |  |  | (20,189 | ) |  |  | (7,925 | ) |  |  | (35,745 | ) |  |  | (7,925 | )
Other income (expense), net |  |  | 6,548 |  |  |  | (632 | ) |  |  | 14,779 |  |  |  | 8,851 |
Total other income (expense), net |  |  | (47,380 | ) |  |  | 99,995 |  |  |  | (112,616 | ) |  |  | 63,492 |
Loss before income taxes |  |  | (181,658 | ) |  |  | (75,544 | ) |  |  | (351,266 | ) |  |  | (111,704 | )
Income tax expense |  |  | 2,100 |  |  |  | — |  |  |  | 2,100 |  |  |  | — |
Net loss |  |  | (183,758 | ) |  |  | (75,544 | ) |  |  | (353,366 | ) |  |  | (111,704 | )
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests |  |  | 1,855 |  |  |  | 2,088 |  |  |  | 4,041 |  |  |  | 3,032 |
Segment net loss attributable to common stockholders of BridgeBio |  | $ | (181,903 | ) |  | $ | (73,456 | ) |  | $ | (349,325 | ) |  | $ | (108,672 | )
Schedule of Inventories Presented on Condensed Consolidated Balance Sheet | Inventories presented on the condensed consolidated balance sheet as of June 30, 2025 consisted of the following balances:
|  | June 30, 2025 |
|  | (in thousands) |
Raw materials |  | $ | 11,463 |
Work in progress |  |  | 1,065 |
Finished goods |  |  | 5,749 |
Total inventories |  | $ | 18,277 |
Customer Concentration Risk |
Summary Of Significant Accounting Policies [Line Items] |
Schedule of Concentration, Percentage of Gross Revenues | The following table summarizes customers that represent 10% or greater of our consolidated total gross revenues:
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Bayer (as described in Note 11) | * |  | 16.7% |  | 30.1% |  | 61.4%
Kyowa Kirin Co., Ltd | * |  | 66.2% |  | * |  | 33.8%
Alexion (as described in Note 11) | 22.3% |  | 14.7% |  | 12.0% |  | *
Customer A | 19.4% |  | * |  | 15.2% |  | *
Customer B | 17.5% |  | * |  | 13.7% |  | *
Customer C | 13.3% |  | * |  | * |  | *
Customer D | 12.2% |  | * |  | 10.1% |  | *
* Represents less than 10% and/or not a customer in the applicable period.
Geographical Risk |
Summary Of Significant Accounting Policies [Line Items] |
Schedule of Concentration, Percentage of Gross Revenues | Total revenues, net is attributed to regions based on the location of our customers or partners.
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
U.S. | 64.7% |  | 17.2% |  | 47.7% |  | 4.8%
Europe, Middle East, and Africa (EMEA) | 31.7% |  | 16.7% |  | 49.4% |  | 61.4%
Asia-Pacific (APAC) | 3.6% |  | 66.1% |  | 2.9% |  | 33.8%
| 100.0% |  | 100.0% |  | 100.0% |  | 100.0%

X
- Definition Schedule of cash, cash equivalents and restricted cash. + References No definition available. + Details
Name: | bbio_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock
Namespace Prefix: | bbio_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of significant accounting policies. + References No definition available. + Details
Name: | bbio_SummaryOfSignificantAccountingPoliciesLineItems
Namespace Prefix: | bbio_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of other current liabilities. + References No definition available. + Details
Name: | us-gaap_OtherCurrentLiabilitiesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details
Name: | us-gaap_ScheduleOfInventoryCurrentTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |